6,7-dihydro-4H-benzo[a]quinolizine-3-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 6,7-dihydro-4H-benzo[a]quinolizine-3-carboxylic acid
• 化学式: C₁₄H₁₃NO₂
• 分子量: 227.26
• InChiKey: YJWNDSVLKFMFCO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION<br/>[FR] NOUVELLES DIHYDROQUINOLIZINONES POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015173164A1

  公开（公告）日：2015-11-19

  The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, X and Y are as described in the description and in the claims, as well as or pharmaceutically acceptable salts, or enantiomers, or diastereomers thereof. The invention also contains compositions including the compounds and methods of using the compounds.

  该发明提供了具有以下一般式的新化合物：其中R1、R2、R3、R4、R5、R6、X和Y如描述和权利要求中所述，以及其药学上可接受的盐，或对映体，或非对映异构体。该发明还包括包括这些化合物的组合物和使用这些化合物的方法。
• Substituted pyridinone-containing trycyclic compounds, and methods using same
  申请人：ARBUTUS BIOPHARMA CORPORATION

  公开号：US10821103B2

  公开（公告）日：2020-11-03

  The present invention includes substituted pyridinone-containing tricyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection in a patient. In certain embodiments, the compounds and compositions of the invention inhibit and/or reduce HBsAg secretion.

  本发明包括可用于治疗或预防患者乙型肝炎病毒（HBV）感染的含取代吡啶酮的三环化合物及其组合物。在某些实施方案中，本发明的化合物和组合物可以抑制和/或减少 HBsAg 的分泌。
• NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
  申请人：F.Hoffmann-La Roche AG

  公开号：EP3099685A1

  公开（公告）日：2016-12-07
• SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME
  申请人：ARBUTUS BIOPHARMA CORPORATION

  公开号：US20190314347A1

  公开（公告）日：2019-10-17

  The present invention includes substituted pyridinone-containing tricyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection in a patient. In certain embodiments, the compounds and compositions of the invention inhibit and/or reduce HBsAg secretion.